drugset / Trial / NCT07736612
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.
Timeline
- Start
- 2026-08-15
- Primary completion
- 2028-08-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | HRS-2329 | Unknown | — | Oral |
| Subject | HS-20093 | Other / unclassified | — | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |